David W. Dodick, MD, FRCP (C), FACP, is Professor of Neurology at the Mayo Clinic College of Medicine and a consultant in neurology at the Mayo Clinic, in Scottsdale, Arizona. He is the Program Director of the Mayo Clinic Neurology Residency Program and Headache Medicine Fellowship Program. He is the Medical Director of the Headache Program and the Sports Neurology and Concussion Program at Mayo Clinic in Arizona. He is an Adjunct Professor and International Chair of Headache in the Department of Neurosciences, Norwegian University of Science and Technology. Dr Dodick is board certified by the Royal College of Physicians and Surgeons of Canada and the American Board of Psychiatry and Neurology (ABPN). He also holds United Council for Neurologic Subspecialties certification in headache medicine and ABPN certification in vascular neurology. Dr Dodick has authored more than 320 peer-reviewed publications and authored/edited 10 books. He is the Chair of the Sports Concussion Conference Workgroup of the American Academy of Neurology and a member of the AAN’s Annual Meeting Committee. He is on the editorial board of several journals including Lancet Neurology, Postgraduate Medicine, Headache, and Cephalalgia. He is President of the International Headache Society, Chair of the American Migraine Foundation, Immediate past-Editor-in-Chief of Cephalalgia, and Past-President of the American Headache Society.« Back to Editorial Board
David Dodick MD, FRCP (C), FACP
Consulting fees: Allergan, Amgen, Alder, Dr Reddy’s, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, INSYS therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, GBS, Colucid, Zosano, eNeura
Royalties: Oxford University Press and Cambridge University Press (Book Royalty)
CME companies honoraria: Haymarket Medical Education, Global Scientific Communications, HealthLogix, Academy for Continued Healthcare Learning
Stock/options: Xalan-GBS, Epien, and Mobile Health
Consulting use agreement: NAS
Board position (advisory; no compensation): King-Devick Test
Articles by David Dodick
- Anti-CGRP therapies – what did we learn in 2020 and what can we expect in 2021?
- CGRP therapies work better in clinical practice than in trials
- Anti-CGRP therapy: where does it fit in our clinics?
- 2017 American Academy of Neurology Annual Meeting: Reduction in migraine days with single dose eptinezumab
- Become a member of CGRP Forum